Qlife Holding AB (publ)

Stockholm Stock Exchange QLIFE.ST

Qlife Holding AB (publ) Free Cash Flow Yield on January 14, 2025: -463.56%

Qlife Holding AB (publ) Free Cash Flow Yield is -463.56% on January 14, 2025, a 99.88% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Qlife Holding AB (publ) 52-week high Free Cash Flow Yield is -273.55% on September 05, 2024, which is 40.99% above the current Free Cash Flow Yield.
Qlife Holding AB (publ) 52-week low Free Cash Flow Yield is -1,530,699.97% on June 28, 2024, which is -330,108.92% below the current Free Cash Flow Yield.
Qlife Holding AB (publ) average Free Cash Flow Yield for the last 52 weeks is -283,225.58%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Stockholm Stock Exchange: QLIFE.ST

Qlife Holding AB (publ)

CEO	Mr. Thomas Warthoe
IPO Date	March 2, 2020
Location	Sweden
Headquarters	Redaregatan 48
Employees	24
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents. The company offers Egoo.Health Platform, an integrated platform with a measuring instrument with disposable capsules and software, where each capsule contains a test for a specific biomarker or virus. Its biomarkers include C-reactive protein home-testing capsule, PHE/Phenylalanine for PKU patients, and Sars-CoV-2/Influenza multiplex for virus/bacteria tests. The company was incorporated in 2019 and is based in Helsingborg, Sweden.

Key trends

Past 5 years